How we grade evidence
- L1 Multiple randomized controlled trials with consistent effect; systematic reviews support the intervention.
- L2 At least one RCT plus larger case series; effect direction consistent but magnitude debated.
- L3 Case series, small pilots, animal data extrapolated; plausible but unproven at scale.
- L4 Testimonial, marketing, or fringe-diagnosis claims without peer-reviewed evidence of benefit.
What a labral tear actually is
The acetabular labrum is a fibrocartilage ring around the hip socket that deepens the joint and helps seal it. Tears usually come from femoroacetabular impingement (FAI) — a bony morphology that pinches the labrum during hip flexion — or from acute trauma. Symptoms include groin pain, clicking, catching, and reduced hip flexion range.
Standard treatment splits into two paths: arthroscopic labral repair or debridement for mechanical symptoms with clear MRI findings and functional limitation, and non-operative management (activity modification, PT focused on hip mechanics, occasional intra-articular injections) for milder cases or patients who prefer to avoid surgery.
Where regenerative therapy is being tried
Cell therapy for labral tears sits at the edge of published evidence. There are small case reports and pilot studies — mostly bone marrow concentrate injected intra-articularly, often combined with PRP — reporting pain and function improvements. There is essentially no randomized trial evidence comparing cell therapy directly to arthroscopy or to conservative care for isolated labral pathology.
Mechanistically, the labrum is poorly vascularized fibrocartilage — the outer third has some blood supply, the inner two-thirds do not. This limits its intrinsic healing capacity and is part of why torn labra generally do not "grow back" on their own. Whether an MSC injection can meaningfully alter that biology is unproven.
Where cell therapy might reasonably fit
- Patient not a surgical candidate (medical comorbidities, personal choice) but symptomatic beyond what PT alone controls.
- Post-arthroscopy patient with persistent symptoms and no clear surgical revision indication.
- Small labral tear with associated early chondral wear, where the goal is broader intra-articular support rather than "healing the tear."
Where it does not reasonably fit
A young patient with a large symptomatic labral tear, positive impingement testing, and clear FAI morphology on imaging is a surgical candidate. Skipping arthroscopy in that population to try cell therapy first is not supported by current evidence and may delay a treatment with much better published outcomes.
Imaging you should have before booking anything
Current MRI (ideally MR arthrogram) within the last 12 months, plus AP pelvis and Dunn view X-rays. Any clinic willing to inject a hip joint for labral pathology without seeing recent imaging is skipping a step that matters.
Cell therapy will not correct impingement morphology. If a CAM lesion or pincer deformity is the underlying driver of your tear, the tear may retear or a new one may form even if the current one improves. This is one of the most common reasons regenerative therapy 'fails' at the hip — the underlying mechanical cause was not addressed.
Regulatory status — Hip labral tear
Weighing labral surgery vs regenerative options?
Send us your imaging findings and symptoms — we'll help you think through the decision honestly.
Ask a question on WhatsApp